The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · see citing works

Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance

Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · see citing works

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Medicare's search for effective obesity treatments: Diets are not the answer.

Mann, T., Tomiyama, A. J., Westling, E., Lew, A.-M., Samuels, B., & Chatman, J. (2007) · American Psychologist · doi:10.1037/0003-066x.62.3.220 · Cited by 1,208 · cited 1× · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Weight Loss Reduces the Risk for Symptomatic Knee Osteoarthritis in Women

Felson, D. T., Zhang, Y., Anthony, J. M., Naimark, A., & Anderson, J. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-7-535 · Cited by 928 · see citing works

Obesity and leptin resistance: distinguishing cause from effect

Myers, M. G., Leibel, R. L., Seeley, R. J., & Schwartz, M. W. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.08.002 · Cited by 906 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · see citing works

Plasma Insulin Response to Oral and Intravenous Glucose Administration1

ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · see citing works

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works

New Interpretation of Oral Glucose Tolerance

Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · see citing works

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724 · see citing works

Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man

EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · see citing works

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans

Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600 · see citing works

The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway

Abbott, C. R., Monteiro, M. P., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · see citing works

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597 · see citing works

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 582 · see citing works

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · see citing works

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works

A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes<subtitle>The Sleep AHEAD Study</subtitle><alt-title>Effect of Weight Loss on Obstructive Sleep Apnea</alt-title>

Foster, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.266 · Cited by 538 · see citing works

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · see citing works

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521 · see citing works

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · see citing works

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Mayo, K. E., Miller, L. J., BATAILLE, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 507 · see citing works

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · see citing works

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion*

Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6643 · Cited by 452 · see citing works

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes

Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · see citing works

The Role of Postprandial Releases of Insulin and Incretin Hormones in Meal-Induced Satiety—Effect of Obesity and Weight Reduction

Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434 · see citing works

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms

I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · see citing works

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works

Insulin resistance and pancreatic cell failure

Kasuga, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29189 · Cited by 412 · see citing works

Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · see citing works

Bariatric Surgery: Risks and Rewards

Pories, W. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1641 · Cited by 405 · see citing works

Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes

Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 402 · see citing works

Attenuated GLP-1 secretion in obesity: cause or consequence

Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394 · see citing works

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works

A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 388 · see citing works

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · see citing works

Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Diabetes · doi:10.2337/db07-1124 · Cited by 353 · see citing works

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · see citing works

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · see citing works

Physical Activity, Body Mass Index, and Risk of Type 2 Diabetes in Patients With Normal or Impaired Glucose Regulation

Hu, G., Lindström, J., Valle, T. T., Eriksson, J. G., Jousilahti, P., Silventoinen, K., Qiao, Q., & Tuomilehto, J. O. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.892 · Cited by 340 · see citing works

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans

Verdich, C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 340 · see citing works

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 334 · see citing works

Point: Visceral Adiposity Is Causally Related to Insulin Resistance

Lebovitz, H. E., & Banerji, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2322 · Cited by 328 · see citing works

The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem

Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307 · see citing works

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · see citing works

Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294 · see citing works

Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain

Runge, S., Thøgersen, H., Madsen, K., Lau, J. F., & Rudolph, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708740200 · Cited by 291 · see citing works

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288 · see citing works

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280 · see citing works

Gastric emptying and obesity

WRIGHT, R. A., Krinsky, S., Fleeman, C., Trujillo, J., & Teague, E. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90141-5 · Cited by 277 · see citing works

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · see citing works

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2005) · Gut · doi:10.1136/gut.2004.059741 · Cited by 275 · see citing works

Role of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion

Anini, Y., & Brubaker, P. L. (2003) · Diabetes · doi:10.2337/diabetes.52.2.252 · Cited by 274 · see citing works

Glucagon gene expression in vertebrate brain.

Drucker, D. J., & Asa, S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68261-4 · Cited by 265 · see citing works

Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms

Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2008) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · see citing works

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 253 · see citing works

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Jacobsen, S. H., Hansen, D. L., Worm, D., Holst, J. J., & Madsbad, S. (2012) · Diabetologia · doi:10.1007/s00125-012-2556-7 · Cited by 241 · see citing works

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J., Holloway, R. H., Besanko, L. K., Burgstad, C. M., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 240 · see citing works

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works

How strong is the association between abdominal obesity and the incidence of type 2 diabetes?

Freemantle, N., Holmes, J., Hockey, A., & Kumar, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01805.x · Cited by 223 · see citing works

GLP-1 and energy balance: an integrated model of short-term and long-term control

Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220 · see citing works

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1

Nakabayashi, H., NISHIZAWA, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 203 · see citing works

An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future

Madsbad, S., Kielgast, U. L., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 201 · see citing works

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

Balkan, B., & Li, X. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1449 · Cited by 201 · see citing works

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Scheen, A. J. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.001 · Cited by 198 · see citing works

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

Knop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 194 · see citing works

Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow

Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 194 · see citing works

Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice

Scott, M. M., Williams, K. W., Rossi, J., Lee, C. E., & Elmquist, J. K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43703 · Cited by 191 · see citing works

Anti-obesity drugs: a review about their effects and their safety

Derosa, G., & Maffioli, P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.675326 · Cited by 185 · see citing works

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake

Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J. J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 182 · see citing works

Arterial Destiffening With Weight Loss in Overweight and Obese Middle-Aged and Older Adults

Dengo, A. L., Dennis, E. A., Orr, J. S., Marinik, E. L., Ehrlich, E., Davy, B. M., & Davy, K. P. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.147850 · Cited by 179 · see citing works

Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2006) · Diabetes · doi:10.2337/db06-0558 · Cited by 178 · see citing works

Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Knudsen, L. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 175 · see citing works

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

Larsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171 · see citing works

Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis: Incretins, gastric emptying and metabolic control

Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164 · see citing works

Muscarinic Receptors Control Postprandial Release of Glucagon-Like Peptide-1: In Vivo and in Vitro Studies in Rats

Anini, Y., Hansotia, T., & Brubaker, P. L. (2002) · Endocrinology · doi:10.1210/endo.143.6.8840 · Cited by 158 · see citing works

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 157 · see citing works

Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients*

ROBERGE, J. N., & Brubaker, P. L. (1991) · Endocrinology · doi:10.1210/endo-128-6-3169 · Cited by 155 · see citing works

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

Wettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153 · see citing works

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 149 · see citing works

Molecular physiology of weight regulation in mice and humans

Leibel, R. L. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.245 · Cited by 138 · see citing works

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · see citing works

Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects

Adam, T. C., & Westerterp‐Plantenga, M. S. (2005) · British Journal Of Nutrition · doi:10.1079/bjn20041335 · Cited by 136 · see citing works

Muscarinic Receptors Control Glucagon-Like Peptide 1 Secretion by Human Endocrine L Cells

Anini, Y., & Brubaker, P. L. (2003) · Endocrinology · doi:10.1210/en.2003-0143 · Cited by 135 · see citing works

Signals that influence food intake and body weight

WOODS, S. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.08.060 · Cited by 131 · see citing works

Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat

Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130 · see citing works

Rapid Oscillations in Plasma Glucagon-Like Peptide-1 (GLP-1) in Humans: Cholinergic Control of GLP-1 Secretion via Muscarinic Receptors1

Balks, H. J., Holst, J. J., Mühlen, A. V. Z., & Brabant, G. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3816 · Cited by 130 · see citing works

Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans

Schirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130 · see citing works

Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus

Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 128 · see citing works

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · see citing works

Glucagon-like Peptide-1 Retards Gastric Emptying and Small Bowel Transit in the Rat (Effect Mediated Through Central or Enteric Nervous Mechanisms)

Tolessa, T., Gutniak, M., Holst, J. J., Efendić, S., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026678925120 · Cited by 123 · see citing works

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

Flint, A., Raben, A., Jf, R., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 120 · see citing works

Distal Small Bowel Hormones (Correlation with Fasting Antroduodenal Motility and Gastric Emptying)

Näslund, E. B., Grybäck, P., Bäckman, L., Jacobsson, H., Juul, J. J., Theodorsson, H. E., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018806129102 · Cited by 116 · see citing works

PYY3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans

Field, B. C. T., Wren, A., Peters, V., Baynes, K., Martin, N. M., Patterson, M., Alsaraf, S., Amber, V., Wynne, K., Ghatei, M. A., et al. (2010) · Diabetes · doi:10.2337/db09-1859 · Cited by 113 · see citing works

Role of the Prohormone Convertase PC3 in the Processing of Proglucagon to Glucagon-like Peptide 1

Rouillé, Y., Kantengwa, S., Irminger, J.-C., & Halban, P. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.32810 · Cited by 109 · see citing works

Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study

Grunberger, G., Chang, A., Soria, G. G., Botros, F. T., Bsharat, R., & Miličević, Z. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03745.x · Cited by 102 · see citing works

Influence of BMI and Gender on Postprandial Hormone Responses

Carroll, J. F., Kaiser, K. A., Franks, S. F., Deere, C., & Caffrey, J. L. (2007) · Obesity · doi:10.1038/oby.2007.355 · Cited by 101 · see citing works

Vagally mediated effects of glucagon‐like peptide 1: in vitro and in vivo gastric actions

Holmes, G. M., Browning, K. N., Tong, M., Qualls‐Creekmore, E., & Travagli, R. A. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.175067 · Cited by 92 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion

Rocca, A. S. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 91 · see citing works

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations

Nyholm, B., Walker, M., Gravholt, C. H., Shearing, P. A., Sturis, J., Alberti, K. G. M. M., Holst, J. J., & Schmitz, O. (1999) · Diabetologia · doi:10.1007/s001250051444 · Cited by 90 · see citing works

Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans

Pannacciulli, N., Bunt, J. C., Koška, J., Bogardus, C., & Krakoff, J. A. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.556 · Cited by 85 · see citing works

Effects of lifestyle intervention on health care costs: improving control with activity and nutrition (ICAN)

Wolf, A. M., Siadaty, M., Yaeger, B., Conaway, M. R., Crowther, J. Q., Nadler, J. L., & Bovbjerg, V. E. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.05.015 · Cited by 79 · see citing works

Rapid Oscillations in Plasma Glucagon-Like Peptide-1 (GLP-1) in Humans: Cholinergic Control of GLP-1 Secretion via Muscarinic Receptors

Balks, H. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.786 · Cited by 71 · see citing works

THE BETA-AGONIST CONTROVERSY

Taylor, D. R., Sears, M. R., & Cockcroft, D. W. (1996) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70465-x · Cited by 70 · see citing works

Pharmaceutical Cost Savings of Treating Obesity with Weight Loss Medications

Greenway, F. L., Ryan, D. H., Bray, G. A., Rood, J. C., Tucker, E. W., & Smith, S. R. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00709.x · Cited by 66 · see citing works

Association of Body Mass and Brain Activation during Gastric Distention: Implications for Obesity

Tomasi, D., Wang, G.-J., Wang, R., Backus, W., Geliebter, A., Telang, F., Jayne, M. C., Wong, C., Fowler, J. S., & Volkow, N. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006847 · Cited by 64 · see citing works

Peripheral versus central cardiorespiratory effects of morphine

Willette, R. N., & Sapru, H. N. (1982) · Neuropharmacology · doi:10.1016/0028-3908(82)90116-2 · Cited by 64 · see citing works

Hepatic‐Portal Vein Infusions of Glucagon‐Like Peptide‐1 Reduce Meal Size and Increase c‐Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats

Baumgartner, I., Pacheco‐López, G., Rüttimann, E. B., Arnold, M., Asarian, L., Langhans, W., Geary, N., & Hillebrand, J. J. G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.01995.x · Cited by 64 · see citing works

Effects of glucagon‐like peptide 1 (7–36 amide) on whole‐body protein metabolism in healthy man

Shalev, A., Holst, J. J., & Keller, U. B. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.540613.x · Cited by 62 · see citing works

The Obesity Epidemic: Pharmacological Challenges

Bloom, S. R., Kuhajda, F. P., Laher, I., Pi-Sunyer, X., Ronnett, G. V., Tan, T., & Weigle, D. S. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.6 · Cited by 59 · see citing works

Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor

Washington, M. C., Raboin, S. J., Thompson, W., Larsen, C. J., & Sayegh, A. I. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.002 · Cited by 58 · see citing works

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58 · see citing works

Impairment of GLP1 ‐induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia

Herzberg-Schäfer, S. A., Heni, M., Stefan, N., Häring, H., & Fritsche, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 56 · see citing works

Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus

Davies, M. J., & Speight, J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01595.x · Cited by 54 · see citing works

Gut Peptides: Targets for Antiobesity Drug Development?

Moran, T. H., & Dailey, M. J. (2009) · Endocrinology · doi:10.1210/en.2009-0003 · Cited by 49 · see citing works

Alterations in energy balance following exenatide administration

Bradley, D. P., Kulstad, R., Racine, N. M., Shenker, Y., Meredith, M., & Schoeller, D. A. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-068 · Cited by 47 · see citing works

The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women

Svendsen, P. F., Jensen, F. K., Holst, J. J., Haugaard, S. B., Nilas, L., & Madsbad, S. (2012) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.691542 · Cited by 46 · see citing works

Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs

Nagell, C. F., Wettergren, A., Ørskov, C., & Holst, J. J. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520500408253 · Cited by 42 · see citing works

Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus

HANSEN, E., Hajri, T., & Abumrad, N. N. (2006) · Surgery · doi:10.1016/j.surg.2005.10.018 · Cited by 41 · see citing works

Muscarinic Receptors Control Postprandial Release of Glucagon-Like Peptide-1: In Vivo and in Vitro Studies in Rats

Anini, Y. (2002) · Endocrinology · doi:10.1210/en.143.6.2420 · Cited by 41 · see citing works

Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity

Tschöp, M. H., & DiMarchi, R. D. (2012) · Diabetes · doi:10.2337/db12-0272 · Cited by 32 · see citing works

Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes

Smushkin, G., Sathananthan, A., Man, C. D., Zinsmeister, A. R., Camilleri, M., Cobelli, C., Rizza, R. A., & Vella, A. V. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2561 · Cited by 32 · see citing works

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7‒36)amide secretion by circulating non-esterified fatty acids

Ranganath, L. R., Norris, F., Morgan, L., WRIGHT, J., & Marks, V. (1999) · Clinical Science · doi:10.1042/cs19980308 · Cited by 20 · see citing works

Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats

Reidelberger, R. D., Haver, A. C., Chelikani, P. K., Apenteng, B. A., Perriotte‐Olson, C., Anders, K., Steenson, S., & Blevins, J. E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00058.2012 · Cited by 19 · see citing works

Sizing Up Pharmacotherapy for Obesity

Valentino, M. A., Terzic, A., & Waldman, S. A. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00191.x · Cited by 4 · see citing works

Type 2 diabetes mellitus

DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · see citing works

Specialized metabolites from the microbiome in health and disease

Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P. C., & Mazmanian, S. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.016 · Cited by 544 · see citing works

Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?

Lean, M. E. J., & Malkova, D. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.220 · Cited by 253 · see citing works

Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249 · see citing works

Acute Exercise and Hormones Related to Appetite Regulation: A Meta-Analysis

Schubert, M. M., Sabapathy, S., Leveritt, M., & Desbrow, B. (2014) · Sports Medicine · doi:10.1007/s40279-013-0120-3 · Cited by 249 · see citing works

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214 · see citing works

Inter‐organ communication: a gatekeeper for metabolic health

Castillo‐Armengol, J., Fajas, L., & Lopez‐Mejia, I. C. (2019) · The EMBO Reports · doi:10.15252/embr.201947903 · Cited by 178 · see citing works

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · see citing works

Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: <scp>A</scp> randomized controlled trial ( <scp>CODEX</scp> )

Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98 · see citing works

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice

Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89 · see citing works

Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress

Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84 · see citing works

Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway

Zhou, J., Poudel, A., Chandramani-Shivalingappa, P., Xu, B., Welchko, R., & Li, L. (2019) · Endocrine · doi:10.1007/s12020-018-1826-7 · Cited by 59 · see citing works

Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59 · see citing works

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49 · see citing works

Therapies for inter-relating diabetes and obesity – GLP-1 and obesity

Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43 · see citing works

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43 · see citing works

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38 · see citing works

Potential contributors to variation in weight‐loss response to liraglutide

Webster, C. M., Mittal, N., Dhurandhar, E. J., & Dhurandhar, N. V. (2023) · Obesity Reviews · doi:10.1111/obr.13568 · Cited by 19 · see citing works

Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity

Seo, D., Faintuch, B. L., Aparecida de Oliveira, E., & Faintuch, J. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.03.002 · Cited by 8 · see citing works

Is liraglutide or exenatide better in type 2 diabetes?

Doggrell, S. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903264051 · Cited by 2 · see citing works

Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.

(2010) · PubMed

P-1405 Glycaemic control improves in type 2 diabetes patients when switching from twice-daily exenatide to once-daily liraglutide

Buse, J. B., Sesti, G., Schmidt, W. E., et al. (2009) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(09)33267-0

Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus

Santoleri, F., Sorice, P., Lasala, R., & Costantini, A. (2014) · Pharmacology &amp Pharmacy · doi:10.4236/pp.2014.54040 · Cited by 3 · see citing works

Pharmacy Cost Differences Associated with the Initiation of Exenatide Once-Weekly Compared to Liraglutide Once-Daily

Loughlin, A. M., Qiao, Q., Grandy, S., et al. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2068